Biotechnology company Ziarco has closed the first round of its series A round with $6m.
UK-based biotechnology company Ziarco has raised $6m of a $27m round from a consortium including drugs company Pfizer’s corporate venturing unit.
Alongside Pfizer Ventures in the series A round for Ziarco was the Biotechnology Value fund.
The deal results in Ziarco entering into an agreement with Pfizer for exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research anti-inflammatory and anti-allergic assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
CORRECTION An earlier version…
